Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

被引：31

作者：

Hann, Hie-Won ^{[1
]}

Wang, Mengjun ^{[2
]}

Hafner, Julie ^{[3
]}

Long, Ronald E. ^{[2
]}

Kim, Su Hee ^{[1
]}

Ahn, Meejin ^{[1
]}

Park, Susan ^{[1
]}

Comunale, Mary Ann ^{[2
]}

Block, Timothy M. ^{[2
]}

Mehta, Anand ^{[2
]}

机构：

[1] Thomas Jefferson Univ Hosp, Liver Dis Prevent Ctr, Div Gastroenterol & Hepatol, Jefferson Med Coll, Philadelphia, PA 19107 USA

[2] Drexel Univ, Coll Med, Doylestown, PA USA

[3] Immunotope Inc, Doylestown, PA USA

来源：

CANCER BIOMARKERS | 2010年 / 7卷 / 06期

关键词：

HEPATOCELLULAR-CARCINOMA; SERUM MARKER; BIOMARKERS;

D O I：

10.3233/CBM-2010-0190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this study. we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in 0P73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

引用

页码：269 / 273

页数：5